<DOC>
	<DOCNO>NCT00033631</DOCNO>
	<brief_summary>RATIONALE : Specialized radiation therapy delivers high dose radiation directly tumor may kill tumor cell cause less damage normal tissue . It yet know dose radiation therapy effective treating stage II prostate cancer . PURPOSE : Randomized phase III trial compare effectiveness two different dos specialize radiation therapy treat patient stage II prostate cancer .</brief_summary>
	<brief_title>Radiation Therapy Treating Patients With Stage II Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival patient stage II adenocarcinoma prostate treat high- vs standard-dose three-dimensional conformal intensity-modulated radiotherapy . - Compare freedom prostate-specific antigen failure , disease-specific survival , local progression , distant metastasis patient treat regimen . - Compare probability tumor control normal tissue complication patient treat regimen . - Compare incidence grade 2 great genitourinary gastrointestinal acute late toxicity patient treat regimen . - Compare quality life , include sexual function , patient treat regimen . - Correlate histopathologic tumor-specific cytogenetic chromosomal marker cancer control outcomes patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord Gleason score prostate-specific antigen ( PSA ) level ( Gleason score 2-6 , PSA ≥10 mg/mL &lt; 20 ng/mL v Gleason score 7 , PSA &lt; 15 ng/mL ) radiation modality ( three-dimensional conformal radiotherapy [ 3D-CRT ] v intensity-modulated radiotherapy [ IMRT ] ) . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo standard-dose 3D-CRT IMRT daily , 5 day week , 7.8 week ( 39 treatment day ) . - Arm II : Patients undergo high-dose 3D-CRT IMRT daily , 5 day week , 8.8 week ( 44 treatment day ) . Quality life ( QOL ) assess initially baseline . After completion radiotherapy , QOL assess every 3 month 1 year every 6 month 4 year . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 1,520 patient ( 760 per treatment arm ) accrue study within 5 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Clinical stage T1bT2b Meets one follow criterion : Gleason score 26 AND prostatespecific antigen ( PSA ) ≥ 10 ng/mL &lt; 20 ng/mL Gleason score 7 AND PSA &lt; 15 ng/mL No regional lymph node involvement No distant metastases PATIENT CHARACTERISTICS : Age : Any age Performance status : Zubrod 01 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No invasive malignancy within past 5 year except localize basal cell squamous cell skin cancer No major medical psychiatric illness would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior cytotoxic chemotherapy No concurrent cytotoxic chemotherapy Endocrine therapy : At least 3 month since prior finasteride No prior hormonal therapy , include : Luteinizing hormonereleasing hormone agonist ( e.g. , goserelin leuprolide ) Antiandrogens ( e.g. , flutamide bicalutamide ) Estrogens ( e.g. , diethylstilbestrol ) No concurrent ( neoadjuvant adjuvant ) hormonal therapy Radiotherapy : No prior pelvic irradiation brachytherapy Surgery : No prior radical surgery ( prostatectomy ) cryosurgery prostate cancer No prior surgical castration ( bilateral orchiectomy ) Other : At least 3 month since prior finasteride phytoestrogen preparation ( PCSPES )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
</DOC>